Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

PreciseOnco The next leap in cancer care: combining multi-modality and spectral imaging, advanced therapies, robotics and AI to enable standardized, precise interventional oncology treatments for cancer patients

Coordinator
Philips Medical Systems Nederland BV, Netherlands
Runs
1 January 2026 to 31 December 2030
Status
Running
EU funding
€14.9m
Total cost
€23.9m
Partners
15 organisations in 6 countries
Type
Research and Innovation Action
Grant agreement
101252582

What the project is doing

In the project's own words, from its summary on CORDIS.

Every year, millions of people around the world face a cancer diagnosis, and for many of them, precise and minimally invasive treatments offer the best hope for recovery. However, delivering these treatments accurately—especially deep inside the body—remains a major challenge. This project, PreciseOnco, aims to revolutionize how doctors plan, guide, and evaluate cancer therapies using the latest breakthroughs in medical imaging and robotics.

At the heart of our work is a new generation of imaging technology, called spectral imaging, which can distinguish between different types of tissue and treatment materials with much greater clarity than current scans. This allows doctors to see tumors more clearly, guide needles with improved accuracy, and monitor treatments in real time. We will also introduce motion correction tools that account for patient breathing and other natural movements during procedures which make the scans sharper, faster, and more reliable.

In addition, we will integrate robotic assistance into treatment workflows to help doctors place needles with sub-millimeter precision. This will reduce variability between operators, shorten procedure times, and make complex treatments more widely accessible, even in smaller hospitals. Our advanced software and AI tools will make it easier to plan, deliver, and confirm treatments without extra scans or delays. We will test these innovations in real-world clinical studies, including treatment of liver and kidney tumors, where today’s tools often fall short.

Ultimately, PreciseOnco aims to make cancer interventions safer, more targeted, and more successful which will offer patients better outcomes with less burden.

Who is involved

OrganisationCityCountryRole
Philips Medical Systems Nederland BVBestNetherlandsCoordinator
Cardiovascular and Interventional Radiological Society of EuropeWienAustriaParticipant
Eibir Gemeinnutzige GmbH Zur Forderung Der Erforschung Der Biomedizinischen BildgebungWienAustriaParticipant
Philips Belgium CommercialBruxellesBelgiumParticipant
Klinikum Der Universitaet Zu KoelnKoelnGermanyParticipant
Philips GmbHHamburgGermanyParticipant
Assistance Publique Hopitaux De ParisParisFranceParticipant
Hospices Civils De LyonLyonFranceParticipant
Philips FranceSuresnesFranceParticipant
Quantum SurgicalMontpellierFranceParticipant
Igea SpACarpi MoItalyParticipant
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant
Philips Electronics Nederland BVEindhovenNetherlandsParticipant
Philips Electronics Nederland BVEindhovenNetherlandsThird party
Universitair Medisch Centrum UtrechtUtrechtNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI